Showing 1,001 - 1,020 results of 1,284 for search '(( significantly ((level decrease) OR (mean decrease)) ) OR ( significant decrease decrease ))~', query time: 0.36s Refine Results
  1. 1001

    Effect of treatments on pH, conductivity, and biological oxygen demand (BOD) over time. by Khomsan Ruangrit (20833447)

    Published 2025
    “…Error bars represent standard deviations from the mean. Letters above the data points represent significant differences between treatments on the same day (Tukey’s HSD test, p <  0.05). …”
  2. 1002

    Data Sheet 1_Fatty infiltration and cross-sectional area as indicators of muscle mass in osteoporosis: a meta-regression study.pdf by Genwen Sun (22678739)

    Published 2025
    “…</p>Results<p>A significant decrease in CSA was observed only in osteoporotic patients compared with controls, and multiple muscle groups were evaluated. …”
  3. 1003

    Supplementary Material for: Patients with Opioid Use Disorder Choosing Treatment with Extended-Release Naltrexone: A 6-Months Naturalistic Study by Brenna I.H. (19773549)

    Published 2024
    “…The majority of the MITT population (84; 60.9%) completed 24 weeks of treatment in the study. There was a significant decrease in the overall use of opioids (p<0.001) and the use of alcohol and other illicit substances was low. …”
  4. 1004

    Related to Fig 1. by Mohammad Nafees Ansari (22232505)

    Published 2025
    “…<p>(<b>A, B</b>) Absolute quantitation (pmol/mg protein) (mean ± SEM, <i>n</i> = 27) of different species of ceramides (A) and glucosylceramides (B) shows higher levels in luminal tumor tissues (labeled as T) in comparison to adjacent normal tissues (labeled as N). …”
  5. 1005

    OVX educes bone density of femur. by Mingzhu Chen (6370013)

    Published 2025
    “…Compared to Sham rats, OVX tats had a significant decrease in bone mass and impaired bone micro structure: (L) BMD, (M) BV, (N) BV/TV, (O) Tb.N,(P) Tb.Sp, and (Q) Tb.Th. …”
  6. 1006
  7. 1007

    5.HT<sub>1A</sub> binding difference between known cause of death (KCOD) controls and SIDS. by Hannah C. Kinney (10280975)

    Published 2025
    “…When SIDS is compared to all KCOD controls, the HG, NTS, and MAO show a significant mean difference in 5-HT<sub>1A</sub> receptor binding. …”
  8. 1008

    Table 2_Cost-effectiveness of the 3E model in diabetes management: a machine learning approach to assess long-term economic impact.docx by Supriya Raghav (21412907)

    Published 2025
    “…</p>Results<p>The 3E model demonstrated significant cost reductions, with the intervention group achieving a 74.3% decrease in total costs compared to 41.8% in the control group while maintaining the same level of glycemic control. …”
  9. 1009

    Table 1_Cost-effectiveness of the 3E model in diabetes management: a machine learning approach to assess long-term economic impact.xlsx by Supriya Raghav (21412907)

    Published 2025
    “…</p>Results<p>The 3E model demonstrated significant cost reductions, with the intervention group achieving a 74.3% decrease in total costs compared to 41.8% in the control group while maintaining the same level of glycemic control. …”
  10. 1010

    Data Sheet 2_The effects of oral medroxyprogesterone acetate combined with conjugated equine estrogens on inflammation in postmenopausal women: a systematic review and meta-analysi... by Jiahui Qiu (7420130)

    Published 2025
    “…</p>Results<p>MPA/CEE treatment was associated with a significant decrease in CRP levels (WMD = -0.173 mg/dL; 95% CI: -0.25 to -0.10; P < 0.001), particularly among postmenopausal women aged <60 years, trials with MPA doses ≤2.5 mg/day, and those with BMI <25 kg/m². …”
  11. 1011

    Data Sheet 1_The effects of oral medroxyprogesterone acetate combined with conjugated equine estrogens on inflammation in postmenopausal women: a systematic review and meta-analysi... by Jiahui Qiu (7420130)

    Published 2025
    “…</p>Results<p>MPA/CEE treatment was associated with a significant decrease in CRP levels (WMD = -0.173 mg/dL; 95% CI: -0.25 to -0.10; P < 0.001), particularly among postmenopausal women aged <60 years, trials with MPA doses ≤2.5 mg/day, and those with BMI <25 kg/m². …”
  12. 1012

    Table 1_The effects of oral medroxyprogesterone acetate combined with conjugated equine estrogens on inflammation in postmenopausal women: a systematic review and meta-analysis of... by Jiahui Qiu (7420130)

    Published 2025
    “…</p>Results<p>MPA/CEE treatment was associated with a significant decrease in CRP levels (WMD = -0.173 mg/dL; 95% CI: -0.25 to -0.10; P < 0.001), particularly among postmenopausal women aged <60 years, trials with MPA doses ≤2.5 mg/day, and those with BMI <25 kg/m². …”
  13. 1013

    Table 2_The effects of oral medroxyprogesterone acetate combined with conjugated equine estrogens on inflammation in postmenopausal women: a systematic review and meta-analysis of... by Jiahui Qiu (7420130)

    Published 2025
    “…</p>Results<p>MPA/CEE treatment was associated with a significant decrease in CRP levels (WMD = -0.173 mg/dL; 95% CI: -0.25 to -0.10; P < 0.001), particularly among postmenopausal women aged <60 years, trials with MPA doses ≤2.5 mg/day, and those with BMI <25 kg/m². …”
  14. 1014

    Supplementary Material for: Preoperative prediction of microvascular invasion in intrahepatic cholangiocarcinoma and its prognostic implications: A multicenter study by figshare admin karger (2628495)

    Published 2025
    “…Stratifying patients by MVI risk—low (no predictors), intermediate (1–3 predictors), and high (4 predictors)— revealed a significant decrease in both recurrence-free and overall survival rates (p<0.001), along with a corresponding increase in early recurrence rates (p<0.001) as the risk level increased. …”
  15. 1015

    Clinical data of lymphoma patients. by Runlong Lin (20796909)

    Published 2025
    “…Post-treatment, the maximum standardized uptake value (SUVmax) and mean standardized uptake value (SUVmean) of the left ventricle significantly increased, and the percentage of patients exhibiting no uptake pattern in the left ventricle significantly decreased, while those with diffuse uptake pattern notably increased. …”
  16. 1016

    Treatment with TCA and S1P2 agonist induces S1PR2 expression and attenuates ROCK1/RHOA expression; inhibition of S1PR2 reverses TCA- or S1P2-mediated effect on ROCK1/RHOA expressio... by Aya Miyagawa-Hayashino (386487)

    Published 2025
    “…The changes in protein levels of RhoA and ROCK1 were not significant. *<i>P</i><0.05 by one-way ANOVA, Dunnett’s multiple comparison test compared with DMSO control in (A) and (B). …”
  17. 1017

    Data Sheet 1_Efficacy of music intervention on pain and anxiety in patients undergoing cataract surgery: a systematic review and meta-analysis.docx by Lanzhu Su (21570704)

    Published 2025
    “…</p>Results<p>Eighteen studies with 2,262 participants were included. Music therapy significantly reduced anxiety levels, as demonstrated by a notable decrease in Visual Analog Scale (VAS) anxiety scores (SMD = -7.10, 95% CI: -12.25 to -1.95) and State-Trait Anxiety Inventory (STAI) scores (SMD = -1.26, 95% CI: -1.85 to -0.66). …”
  18. 1018

    Supplementary file 1_Wellness-enhancing effects of the canine growth hormone releasing hormone therapy mediated by plasmid and electroporation in healthy old dogs.docx by Min-Ok Ryu (5072594)

    Published 2025
    “…While mean serum IGF-1 concentrations did not change overall, post-hoc stratification revealed that dogs with low baseline IGF-1 (<90 ng/mL) showed substantial increases, whereas those with high baseline levels tended to decrease. …”
  19. 1019

    Image1_The clinical and genetic aspects of six individuals with GH1 variants and isolated growth hormone deficiency type II.tif by Xiaozhen Huang (5858690)

    Published 2024
    “…Background<p>Isolated growth hormone deficiency type II (IGHD II) is an autosomal dominant disorder characterized by a GH1 gene variant resulting in a significant reduction in growth hormone (GH) secretion and a subsequent decrease of plasma insulin-like growth factor 1 (IGF-1) levels and eventual growth impairment.…”
  20. 1020

    Table1_The clinical and genetic aspects of six individuals with GH1 variants and isolated growth hormone deficiency type II.docx by Xiaozhen Huang (5858690)

    Published 2024
    “…Background<p>Isolated growth hormone deficiency type II (IGHD II) is an autosomal dominant disorder characterized by a GH1 gene variant resulting in a significant reduction in growth hormone (GH) secretion and a subsequent decrease of plasma insulin-like growth factor 1 (IGF-1) levels and eventual growth impairment.…”